Eli Lilly’s Zepbound outperforms Novo’s Wegovy for weight loss in head-to-head trial Posted on December 4, 2024 by wpadmin zimmytws/iStock Editorial via Getty Images Update: Adds statement from Novo Nordisk. Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Danish rival Novo Nordisk’s (NVO) Wegovy (semaglutide) in the first head-to-head trial of the
